Scientific Library
- Acute Coronary Syndrom
- ASCVD Prevention
- Bifurcation Stenting
- Cardio-Oncology
- Congestive Heart Failure
- DAPT Duration
- Drug Coated Balloon
- Fractional Flow Reserve
- IVUS Guidance
- Optical Coherence Tomography
- Pulmonary Hypertension
- Rotational Atherectomy
- Shear Stress
- Stenting Left Main
- Transcatheter Aortic Valve Replacement
- Percutaneous LAA Occlusion
- Mitral/Tricuspid Valvular Disease
- Other Relevant Articles
-
Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trialJ Silvain, B Lattuca, ALPHEUS investigators et al. -
ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stentingSchulz-Schüpke S, Byrne RA, ntracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) Trial Investigators.
-
6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical TrialHong SJ, Shin DH, IVUS-XPL Investigators.
-
'Ticagrelor alone vs. dual antiplatelet therapy from 1 month after drug-eluting coronary stenting among patients with STEMI': a post hoc analysis of the randomized GLOBAL LEADERS trialAS Gamal, H Hara, PW Serruys et al.
-
Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trialCollet JP, Silvain J, ARCTIC investigators.
-
Long-term dual antiplatelet-induced intestinal injury resulting in translocation of intestinal bacteria into blood circulation increased the incidence of adverse events after PCI in patients with coronary artery diseaseYiY Zheng, TT Wu, X Xie et al.
-
Cost-Effectiveness of Different Durations of Dual-Antiplatelet Use After Percutaneous Coronary InterventionArbel Y, Bennell MC, Wijeysundera HC et al.
-
Patient-tailored antithrombotic therapy following percutaneous coronary interventionNMR van der Sangen, R Rozemeijer, DRPP CP Yin et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
